BFM
REGN icon

Boothbay Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Boothbay Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
+2,972
New +$2.28M 0.03% 560
2025
Q4 		– Sell
-4,240
Closed -$2.38M – 2284
2025
Q3 		$2.38M Buy
4,240
+1,541
+57% +$871K 0.03% 525
2025
Q2 		$1.42M Buy
+2,699
New +$1.51M 0.03% 585
2025
Q1 		– Sell
-12,375
Closed -$8.82M – 1713
2024
Q4 		$8.82M Buy
12,375
+11,239
+989% +$9.43M 0.22% 123
2024
Q3 		$1.19M Buy
+1,136
New +$1.26M 0.03% 699
2024
Q2 		– Sell
-5,081
Closed -$4.89M – 1807
2024
Q1 		$4.89M Buy
+5,081
New +$4.83M 0.09% 233
2023
Q3 		– Sell
-10,590
Closed -$7.61M – 2014
2023
Q2 		$7.61M Buy
10,590
+10,226
+2,809% +$7.88M 0.17% 119
2023
Q1 		$299K Buy
364
+80
+28% +$60.3K 0.01% 1505
2022
Q4 		$205K Buy
+284
New +$210K ﹤0.01% 1604
2020
Q3 		– Sell
-4,000
Closed -$2.5M – 1188
2020
Q2 		$2.5M Sell
4,000
-1,000
-20% -$568K 0.17% 154
2020
Q1 		$2.44M Sell
5,000
-2,000
-29% -$825K 0.2% 127
2019
Q4 		$2.63M Sell
7,000
-2
-0% -$673 0.23% 110
2019
Q3 		$1.94M Buy
7,002
+887
+15% +$262K 0.18% 152
2019
Q2 		$1.91M Buy
+6,115
New +$2.04M 0.17% 149

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Boothbay Fund Management's REGN Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 2,972 shares worth $2.3M. The stake represents 0.03% of the portfolio and ranks #560 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in REGN as recently as Q3 2025.

Boothbay Fund Management first reported a position in REGN in Q2 2019 and has held it in 14 quarters since. The position peaked at $8.82M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Boothbay Fund Management held 2,972 shares of Regeneron Pharmaceuticals worth $2.3M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #560 holding.
  • Boothbay Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • Boothbay Fund Management's Regeneron Pharmaceuticals position peaked at $8.82M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.